Vanguard Group Inc. Sells 283,775 Shares of Edwards Lifesciences Corporation $EW

Vanguard Group Inc. reduced its stake in Edwards Lifesciences Corporation by 0.4% in the fourth quarter, selling 283,775 shares but still holding over 70 million shares valued at approximately $5.97 billion. Despite this sale, Edwards Lifesciences reported strong Q1 earnings, beating analyst estimates and raising its full-year 2026 guidance, along with announcing a $500M accelerated share repurchase program. The company faces some insider selling and cost-of-sales pressures, but analysts generally maintain a “Moderate Buy” rating with a consensus price target around $95.39.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin